Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rezatapopt + pembrolizumab
- Development stage
- Unknown
- Lead developer
- PMV Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**rezatapopt + pembrolizumab** is an investigational combination treatment composed of rezatapopt (INN: PC14586), a small molecule targeting mutant p53 (specifically TP53 Y220C), plus pembrolizumab, a humanized anti-PD-1 monoclonal antibody. Rezatapopt is orally administered and designed to restore wild-type function to mutant p53 proteins found in certain advanced solid tumors. Pembrolizumab is administered intravenously and works as an immune checkpoint inhibitor, enhancing antitumor immune responses by blocking PD-1 interaction with PD-L1/L2. The combination is being explored for synergy, especially in patients with advanced solid tumors harboring the TP53 Y220C mutation[1][3].
- Other names
- rezatapopt + pembrolizumabPC14586 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on rezatapopt + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rezatapopt + pembrolizumab.